Business Context and Reporting Period
Company: Incyte Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Incyte is focused on the discovery and development of novel small molecule drugs for HIV, inflammatory disorders, cancer, and diabetes. The company is transitioning from an information products business to a drug discovery and development model. In January 2005, the company sold its Proteome facility, which is now reported as a discontinued operation.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2005 |
Six Months Ended June 30, 2004 |
|---|---|---|---|
| Revenues | $2,676 | $5,591 | $9,488 |
| Net Loss | $(25,145) | $(45,276) | $(101,315) |
| Net Loss Per Share (Basic/Diluted) | $(0.30) | $(0.54) | $(1.39) |
| Cash and Cash Equivalents | $37,177 | $37,177 | $152,933 |
| Marketable Securities | $364,272 | $364,272 | $337,584 |
| Total Debt (Convertible Notes) | $349,506 | $349,506 | $378,766 |
| Stockholders' Equity | $33,751 | $33,751 | $78,517 |
Liquidity: As of June 30, 2005, the company held $401.4 million in cash, cash equivalents, and marketable securities. Management believes these resources are adequate to satisfy capital needs for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased to $5.6 million for the six months ended June 30, 2005, from $9.5 million in the prior year period. This decline is attributed to the closure of the Palo Alto facility and the strategic decision to discontinue information products.
- Reduced Net Loss: The net loss improved significantly to $45.3 million (six months 2005) from $101.3 million (six months 2004). This improvement is primarily due to a reduction in "Other expenses" related to restructuring charges, which dropped from $42.7 million in 2004 to $0.8 million in 2005.
- Operating Expenses: Total costs and expenses decreased to $50.6 million (six months 2005) from $103.3 million (six months 2004). Research and development expenses increased slightly due to expanded drug discovery programs, while Selling, General, and Administrative (SG&A) expenses decreased due to restructuring efficiencies.
- Debt Repurchase: The company repurchased $29.0 million in face value of its 5.5% convertible subordinated notes during the second quarter of 2005, resulting in a gain of $0.4 million.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Reverset: The most advanced product candidate (HIV treatment) is in Phase IIb trials. The company plans an end-of-Phase II meeting with the FDA in Q3 2005 and anticipates initiating Phase III trials in Q4 2005.
- Other Programs: Phase IIa trials initiated for a CCR2 antagonist (inflammation/diabetes) and a Phase I trial for a sheddase inhibitor (cancer).
- Financial Expectations: The company anticipates incurring additional losses for several years as it expands drug discovery programs. Revenues from information products are expected to continue declining.
Risks and Contingencies:
- Litigation: Invitrogen Corporation has filed a patent infringement suit (stayed pending appeal). The company cannot estimate potential damages. An arbitration with Iconix Pharmaceuticals was settled in January 2005 with no material financial impact.
- Capital Needs: The company will likely need to raise additional capital in the future to fund operations and debt service obligations. Failure to do so could limit R&D efforts.
- Debt Obligations: Significant contractual obligations include $349.1 million in principal on convertible subordinated debt and substantial lease commitments for vacated space.
- Accounting Changes: The company is evaluating the impact of SFAS No. 123R (Share-Based Payment), which is expected to have a material impact on financial results upon adoption in 2006.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $401.4 million cash position against the projected $46.4 million cash burn from operations in the first half of 2005.
- Debt Maturity: Confirm the status of the $99.1 million in 5.5% notes due in 2007 and the $250.0 million in 3.875% notes due in 2011.
- Restructuring Accruals: Review the remaining accrued restructuring liabilities of approximately $29.6 million ($14.5M from 2004 program + $15.1M from 2002 program) to ensure adequate funding for lease terminations and severance.
- Clinical Milestones: Monitor the timeline for the FDA end-of-Phase II meeting for Reverset and the initiation of Phase III trials as scheduled for late 2005.
- Contingent Liabilities: Assess the potential financial impact of the Invitrogen litigation if the stay is lifted and the case proceeds.